Reports
Sale
Latin America Vaccine Market Share, Size, Analysis, Forecast: By Technology: Recombinant and Conjugate Vaccine, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Others; By Indication: Pneumococcal Disease, Influenza, Human Papilloma Virus, Others; By End User; Regional Analysis; Competitive Landscape; 2024-2032
Latin America Vaccine Market Outlook
The Latin America vaccine market size reached a value of approximately USD 5.59 billion in 2023. The market is expected to grow at a CAGR of 7.2% between 2024 and 2032, reaching a value of around USD 10.41 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Trends in the Market
A vaccine is a preparation that is designed to stimulate an immune system response in the recipient’s body, protecting against a more severe reaction or infection upon contact with the antigen in other circumstances. The duration of effect of vaccines can vary, while some may be recommended to be re-taken at specific intervals, others can offer long-term protection. Based on prevalent antigens and illnesses, recommended vaccines may vary.
- The need for vaccines is primarily being driven by the increased prevalence of various infectious illnesses. The Latin America vaccine market is being further stimulated by the growing consumer awareness of the benefits of timely vaccinations to protect against various illnesses.
- Improvements in healthcare infrastructure are enhancing the accessibility and availability of vaccines throughout the Latin America region. Expansion of healthcare centres are enabling more patients, of all ages, to seek out vaccines in a timely manner.
- The rapid development of homegrown vaccines are providing lucrative opportunities to the Latin America vaccine market. Pharmaceutical companies in countries such as Brazil, Mexico, and Cuba are developing their own vaccines which undergo clinical trials and approvals from coordinating regulators.
Latin America Vaccine Market Analysis
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on technology, the market is divided into recombinant and conjugate vaccine, inactivated vaccines, live attenuated vaccines, and toxoid vaccines, among others. The market on the basis of indication is segmented into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DPT), polio, hepatitis, and JE (Japanese Encephalitis) vaccine, among others. On the basis of end user, the market is segmented into paediatric vaccine, adult vaccine, and travellers vaccine. By country, the market is divided into Brazil, Argentina, and Mexico.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the Latin America vaccine market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.
- GlaxoSmithKline plc
- Novartis AG
- Pfizer Laboratories Ltd
- Sanofi
- AstraZeneca plc.
- Others
Market Share by Technology
Inactivated vaccines, by technology, are expected to account for a sizable share of the Latin America vaccine market due to their accessibility, affordability, and stability. These vaccines significantly reduce the probability of virulence reversal following immunisation because of their ability to stop pathogen reproduction. With the use of adjuvants like specific kinds of oils or aluminium hydroxide, the immunity brought on by inactivated vaccines can be further strengthened. However, for inactivated vaccines to work well, significant care must be taken during preparation, storage, and handling.
Recombinant and conjugate vaccines are likely to grow at a fast rate in the because of their expanding use in the region. Increase in support from various governments and rising investments in conjugate vaccines are some of the factors that are supporting their growth.
Market Share by Indication
With the increase in seasonal influenza cases and the growing number of recommendations for vaccination against the disease, influenza is expected to account for a significant portion of the Latin America vaccine market. One of the major factors influencing market expansion is the rising number of government programmes to boost influenza vaccination and various governments efforts to improve the supply, administration, and distribution of the vaccine. As influenza spreads easily and the vaccine is required to be retaken, there is a recuring demand that is likely to grow further in coming years as more people in the region adopt regular vaccination schedules for influenza.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
GlaxoSmithKline plc, established in 2000 with headquarters in Brentford, United Kingdom, is one of the biggest research-based pharmaceutical firms in the world that produces, promotes, and distributes products for human health. It creates novel vaccinations and specialised medications for the purpose of preventing and treating diseases. They operate three multinational companies that conduct research, develop, and produce cutting-edge pharmaceutical drugs, vaccines, and consumer healthcare items.
Novartis AG, with its headquarters in Basel, Switzerland was founded in 1996. A leading global company specialising in medicine, the company uses innovative science and digital technologies to create transformative treatments in areas of great need. It employs cutting-edge research and digital technology as a major global pharmaceutical firm to develop game-changing medications when there is an urgent medical need.
AstraZeneca plc was founded in 1999 and is headquartered in Cambridge, United Kingdom, with a focus on the creation, production, and research of pharmaceutical products. The company develops, produces, and sells pharmaceutical and biotechnology products to treat cancer, cardiovascular conditions, infections, neurological conditions, respiratory conditions, gastrointestinal conditions, and inflammatory conditions.
Other market players include Pfizer Laboratories Ltd, and Sanofi, among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Technology |
|
| Breakup by Indication |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
7 Opportunities and Challenges in the Market
8 Global Vaccine Market Overview
8.1 Key Industry Highlights
8.2 Global Vaccine Historical Market (2017-2023)
8.3 Global Vaccine Market Forecast (2024-2032)
9 Latin America Vaccine Market Analysis
9.1 Key Industry Highlights
9.2 Latin America Vaccine Historical Market (2017-2023)
9.3 Latin America Vaccine Market Forecast (2024-2032)
10 Latin America Vaccine Market by Technology
10.1 Recombinant and Conjugate Vaccine
10.1.1 Market Share
10.1.2 Historical Trend (2017-2023)
10.1.3 Forecast Trend (2024-2032)
10.2 Inactivated Vaccines
10.2.1 Market Share
10.2.2 Historical Trend (2017-2023)
10.2.3 Forecast Trend (2024-2032)
10.3 Live Attenuated Vaccines
10.3.1 Market Share
10.3.2 Historical Trend (2017-2023)
10.3.3 Forecast Trend (2024-2032)
10.4 Toxoid Vaccines
10.4.1 Market Share
10.4.2 Historical Trend (2017-2023)
10.4.3 Forecast Trend (2024-2032)
10.5 Others
11 Latin America Vaccine Market by Indication
11.1 Pneumococcal Disease
11.1.1 Market Share
11.1.2 Historical Trend (2017-2023)
11.1.3 Forecast Trend (2024-2032)
11.2 Influenza
11.2.1 Market Share
11.2.2 Historical Trend (2017-2023)
11.2.3 Forecast Trend (2024-2032)
11.3 Human Papilloma Virus
11.3.1 Market Share
11.3.2 Historical Trend (2017-2023)
11.3.3 Forecast Trend (2024-2032)
11.4 Meningococcal Disease
11.4.1 Market Share
11.4.2 Historical Trend (2017-2023)
11.4.3 Forecast Trend (2024-2032)
11.5 Rotavirus
11.5.1 Market Share
11.5.2 Historical Trend (2017-2023)
11.5.3 Forecast Trend (2024-2032)
11.6 Varicella, Measles, Mumps, and Rubella
11.6.1 Market Share
11.6.2 Historical Trend (2017-2023)
11.6.3 Forecast Trend (2024-2032)
11.7 Diphtheria, Pertussis, and Tetanus (DPT)
11.7.1 Market Share
11.7.2 Historical Trend (2017-2023)
11.7.3 Forecast Trend (2024-2032)
11.8 Polio
11.8.1 Market Share
11.8.2 Historical Trend (2017-2023)
11.8.3 Forecast Trend (2024-2032)
11.9 Hepatitis
11.9.1 Market Share
11.9.2 Historical Trend (2017-2023)
11.9.3 Forecast Trend (2024-2032)
11.10 JE (Japanese Encephalitis) Vaccine
11.10.1 Market Share
11.10.2 Historical Trend (2017-2023)
11.10.3 Forecast Trend (2024-2032)
11.11 Others
12 Latin America Vaccine Market by End User
12.1 Paediatric Vaccine
12.1.1 Market Share
12.1.2 Historical Trend (2017-2023)
12.1.3 Forecast Trend (2024-2032)
12.2 Adult Vaccine
12.2.1 Market Share
12.2.2 Historical Trend (2017-2023)
12.2.3 Forecast Trend (2024-2032)
12.3 Travellers Vaccine
12.3.1 Market Share
12.3.2 Historical Trend (2017-2023)
12.3.3 Forecast Trend (2024-2032)
13 Latin America Vaccine Market by Country
13.1 Brazil
13.1.1 Market Share
13.1.2 Historical Trend (2017-2023)
13.1.3 Forecast Trend (2024-2032)
13.2 Argentina
13.2.1 Market Share
13.2.2 Historical Trend (2017-2023)
13.2.3 Forecast Trend (2024-2032)
13.3 Mexico
13.3.1 Market Share
13.3.2 Historical Trend (2017-2023)
13.3.3 Forecast Trend (2024-2032)
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 GlaxoSmithKline plc
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Novartis AG
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Pfizer Laboratories Ltd
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Sanofi
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 AstraZeneca plc.
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Latin America Vaccine Market: Key Industry Highlights, 2017 and 2032
2. Latin America Vaccine Historical Market: Breakup by Technology (USD Million), 2017-2023
3. Latin America Vaccine Market Forecast: Breakup by Technology (USD Million), 2024-2032
4. Latin America Vaccine Historical Market: Breakup by Indication (USD Million), 2017-2023
5. Latin America Vaccine Market Forecast: Breakup by Indication (USD Million), 2024-2032
6. Latin America Vaccine Historical Market: Breakup by End User (USD Million), 2017-2023
7. Latin America Vaccine Market Forecast: Breakup by End User (USD Million), 2024-2032
8. Latin America Vaccine Historical Market: Breakup by Country (USD Million), 2017-2023
9. Latin America Vaccine Market Forecast: Breakup by Country (USD Million), 2024-2032
10. Latin America Vaccine Market Structure
Key Questions Answered in the Report
In 2023, the Latin America market for vaccines attained a value of nearly USD 5.59 billion.
The market is projected to grow at a CAGR of 7.2% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 10.41 billion by 2032.
The major drivers of the Latin America vaccine market include the growing consumer awareness of the benefits of vaccines, improvements in healthcare infrastructure, and rising initiatives by both public and private organisations.
The increased prevalence of various infectious illnesses and growing research and development efforts for new vaccines are the key trends propelling the growth of the market.
The various technologies of vaccines in the market are recombinant and conjugate vaccine, inactivated vaccines, live attenuated vaccines, and toxoid vaccines, among others.
The major countries in the market are Brazil, Argentina, and Mexico.
Vaccines include a harmless form of the bacteria or virus that causes the illness that patients are immunised against, protecting them from the full effects of the illness.
The most well-known example of a highly effective vaccination is smallpox immunisation with vaccinia virus.
The major players in the market are GlaxoSmithKline plc, Novartis AG, Pfizer Laboratories Ltd, Sanofi, and AstraZeneca plc., among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER